Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeisVac-C Single Priming Dose in Infants
NCT01218451Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2010
- Primary completion
- Jan 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of Meningococcal group C polysaccharide conjugate vaccine in Meningococcal disease serogroup C (MenC), sponsored by Pfizer. Started Sep 2010; status: completed.
02
Drugs
Meningococcal group C polysaccharide conjugate vaccine
03
Conditions
Meningococcal disease serogroup C (MenC)
Beyond the preview
Go deeper on NCT01218451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01218451.